Iclusig Approval History

• FDA approved: Yes (First approved December 14th, 2012)
• Brand name: Iclusig
• Generic name: ponatinib
• Company: Ariad Pharmaceuticals, Inc.
• Treatment for: Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia

Iclusig (ponatinib) is a kinase inhibitor for the treatment of chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).

FDA Approval History for Iclusig

Date	Article
Dec 14, 2012	FDA Approves Iclusig to Treat Two Rare Types of Leukemia
Oct 24, 2012	ARIAD Announces U.S. Food and Drug Administration Acceptance of NDA Filing for Ponatinib
Aug 13, 2012	Ariad Announces Submission of New Drug Application for Ponatinib to the U.S. Food and Drug Administration

See also...

Iclusig (ponatinib) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.